share_log

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

诺瓦·门蒂斯对政府决定成立罕见病咨询小组表示赞赏
newsfile ·  2023/11/03 20:30

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group (IAG) for drugs for rare diseases, as part of its National Strategy to help facilitate information sharing and improve access and affordability of effective drugs for rare diseases across the country.

不列颠哥伦比亚省温哥华--(新闻文件公司-2023 年 11 月 3 日)- Nova Mentis Life Science Corp.(CSE:NOVA)(FSE:HN3Q)(OTCQB:NMLSF)(“NOVA” 或 “公司”), 加拿大政府作为其国家战略的一部分,成立了新的罕见病药物实施咨询小组(IAG),这是其国家战略的一部分,旨在帮助促进信息共享,改善全国范围内罕见病有效药物的可及性和可负担性,这是一家生物技术公司,也是基于裸盖洛西宾的神经炎症性疾病治疗和补充诊断领域的全球领导者,加拿大政府对此感到高兴。

As part of this overall investment, the Government of Canada will make available up to $1.4 billion to provinces and territories through bilateral agreements. This funding will help provinces and territories improve access to new and emerging drugs, as well as support enhanced access to existing drugs, early diagnosis, and screening for rare diseases.

作为这项总体投资的一部分,加拿大政府将通过双边协议向各省和地区提供高达14亿加元的资金。这笔资金将帮助各省和地区改善获得新兴药物的机会,并支持增加获得现有药物、早期诊断和罕见病筛查的机会。

"NOVA has dedicated its research and drug development efforts to improving quality of life and public health outcomes for those with fragile x syndrome (FXS), a rare disease and the leading genetic cause of autism spectrum disorder (ASD). We applaud the Canadian government for prioritizing families who are dealing with rare diseases and trying to meet the increasing need for effective therapeutic solutions," says CEO, Will Rascan.

“NOVA一直致力于研究和药物开发工作,以改善脆性x综合征(FXS)患者的生活质量和公共卫生结果,脆性x综合征是一种罕见疾病,也是自闭症谱系障碍(ASD)的主要遗传原因。我们赞扬加拿大政府优先考虑患有罕见疾病并努力满足对有效治疗解决方案日益增长的需求的家庭,” 首席执行官威尔·拉斯坎说。

NOVA is the first company in the world conducting a human trial investigating the effects of psilocybin on the cognitive and behavioural symptoms associated with FXS. The clinical trial is currently recruiting participants to assess repetitive, oral microdose psilocybin therapy on adults diagnosed with FXS. The Company intends to validate behavioural testing with state-of-the-art diagnostic and therapeutic biomarker technology, and machine learning artificial intelligence (AI).

NOVA是世界上第一家进行人体试验的公司,该试验研究迷幻药对与FXS相关的认知和行为症状的影响。该临床试验目前正在招募参与者,以评估对被诊断患有FXS的成年人进行重复的口服微剂量psilocybin疗法。该公司打算使用最先进的诊断和治疗生物标志物技术以及机器学习人工智能(AI)来验证行为测试。

NOVA is the first biotech company in the world to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of FXS. Orphan drugs are drugs that are developed specifically to treat rare diseases.

NOVA是世界上第一家因使用psilocybin治疗FXS而在美国和欧盟获得孤儿药称号的生物技术公司。孤儿药是专门为治疗罕见疾病而开发的药物。

About Nova Mentis Life Science Corp.

关于 Nova Mentis 生命科学公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis Life Science Corp. 是一家总部位于加拿大的生物技术公司,也是开发神经炎症性疾病诊断和基于psilocybin的疗法的全球领导者。Nova是第一家在美国和欧盟因使用psilocybin治疗脆性X综合征(FXS)而获得孤儿药称号的生物技术公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

NOVA的目标是诊断和治疗医疗需求未得到满足的使人衰弱的慢性病,例如自闭症谱系障碍(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

有关公司的更多信息,请访问或发送电子邮件至 info@novamentis.ca。

On Behalf of the Board

代表董事会

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

总裁兼首席执行官威尔·拉斯坎
Nova Mentis 生命科学公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

电话:778-819-0244
免费电话:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
脸书:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大证券交易所及其市场监管机构(该术语在加拿大证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新闻稿包含构成 “前瞻性陈述” 的陈述。此类前瞻性陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致Nova Mentis Life Science的实际业绩、业绩或成就或行业发展与此类前瞻性陈述所表达或暗示的预期结果、业绩或成就存在重大差异。前瞻性陈述是非历史事实的陈述,通常但并非总是以 “期望”、“计划”、“预期”、“相信”、“打算”、“估计”、“项目”、“潜在” 和类似的表达方式来识别,或者事件或条件 “将”、“可能” 或 “应该” 发生。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发